Today, we shared results from an interim analysis in our Phase 3 RAISE trial. Read more in our press release: https://lnkd.in/e6wghvQH We would like to extend our sincere gratitude to the patients, investigators and clinical sites who supported and participated in the trial. We look forward to sharing results from the full dataset in the coming months to help inform future status epilepticus research.
Marinus Pharma
Pharmaceutical Manufacturing
Radnor, PA 9,358 followers
Dedicated to the development of innovative therapeutics to treat seizure disorders
About us
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
- Website
-
http://www.marinuspharma.com
External link for Marinus Pharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Radnor, PA
- Type
- Public Company
Locations
-
Primary
5 Radnor Corporate Center, 100 Matsonford Rd
Suite 500
Radnor, PA 19087, US
Employees at Marinus Pharma
-
Katie Jepsen
Sr. Director, Commercial Product & Strategy at Marinus Pharma
-
Michael Saporito
Vice President of Research and Preclinical Development at Marinus Pharma
-
Marc Bellisario
Program manager and technical leader with over 20 years' experience developing and launching products in the medical devices and biopharmaceuticals…
-
Christy Shafer
Chief Commercial Officer at Marinus Pharma
Updates
-
Join us next week at the American Academy of Neurology Conference to learn more about our Phase 3 clinical studies and how we’re innovating to drive progress for a new potential treatment for patients with refractory status epilepticus.
-
Stop by our table and presentation at the Status Epilepticus Colloquium to learn more about our ongoing clinical development of an investigational neuroactive steroid for the treatment of refractory status epilepticus. #StatusepilepticusColloquium
-
This #WorldHealthDay, we stand with families affected by seizure disorders and other rare diseases. We are dedicated to pioneering innovative treatment options that help address the unmet medical needs of those facing these challenges. Together, let’s spread awareness, understanding and compassion for a healthier, more equitable world.
-
We’re pleased to announce that Marinus was selected as a finalist for the 2024 Citeline Awards in the Excellence in Rare Disease Drug Development category. We’re honored to be recognized amongst top innovators in the space. #CitelineAwards
-
Recently, our Executive Director of Regulatory Affairs, Christine Kampf, participated in an engaging panel at DIA Europe 2024 as part of the European Regulatory Town Hall, speaking about new pharmaceutical legislation and access to novel healthcare in Europe.
-
At Marinus, we recognize the challenges faced by individuals affected by epilepsy, their caregivers, and the importance of providing innovative new treatment options. We’re committed to raising awareness and delivering solutions that address unmet medical needs for these families. #PurpleDay #EpilepsyAwareness
-
This Wednesday, our Chief Business Officer, Thomas J Lyons, will be speaking at Reuters Events Pharma USA 2024. Stop by to hear his approach to leveraging internal and external partnerships that drive a patient-first pharma culture. #REpharmaUSA
-
The Marinus team recently attended the Epilepsy Foundation Eastern Pennsylvania Mardi Gras Gala in Philadelphia, PA and the NYU Langone Health FACES Gala in New York, NY. We are grateful for opportunities to show support and raise awareness to help overcome the challenges of living with epilepsy. #EpilepsyAwareness
-
Visit our booth at AANN: American Association of Neuroscience Nurses to learn more about our important work in status epilepticus and CDKL5 deficiency disorder, a reflection of our commitment to help improve outcomes for individuals affected by seizure disorders.